Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05738798
Other study ID # NL81774.075.22
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date July 1, 2025

Study information

Verified date February 2023
Source Deventer Ziekenhuis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about oral immunotherapy in food allergic children < 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Participants will receive oral immunotherapy for 1 year with a maintenance dose of 300 mg allergenic protein and are compared with food allergic infants not receiving oral immunotherapy to compare with natural tolerance development.


Description:

Primary objective: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction in children under the age of 30 months with an established food allergy compared to routine care? Secondary objective: What is the effect of early low-dose oral immunotherapy in children under the age of 30 months with an established food allergy on (allergy specific) quality of life of parents and children compared to routine care? Study design: randomized controlled superiority trial Study population: Children between 9 and 30 months old with an IgE-mediated food allergy to peanut, tree nuts, cow's milk and/or hen's egg as proven by an oral food challenge. Intervention: 1-year low-dose oral immunotherapy (daily 300 mg allergenic protein) compared to strict avoidance in the control group. Main study parameters/endpoints: Long-term tolerance as assessed by an exit oral food challenge at 4 weeks after discontinuation of the oral immunotherapy, combined with uncomplicated consumption of a full dose of the specific food at 6 months after discontinuation of the therapy.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date July 1, 2025
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 9 Months to 30 Months
Eligibility Inclusion Criteria: - An IgE-mediated food allergy to peanut, cashew, hazelnut, walnut, cow's milk and/or hen's egg as proven by sensitization to the specific allergen (sIgE > 0.35kU/l) and a positive oral food challenge. - The fore-mentioned allergens are introduced into the diet of the child (the child is tolerant for the specific allergen(s)), or the child is diagnosed with a food allergy for the specific allergen(s). Exclusion Criteria: - (Suspected) eosinophilic oesophagitis - Uncontrolled asthma/ viral wheeze. - The inability of parents to follow instructions, recognize allergic reactions or administer emergency medication. - Participation in any other intervention study at the time of the OIT study, with the exception of studies on guided early introduction of highly allergenic foods.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
oral immunotherapy
oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.

Locations

Country Name City State
Netherlands Amsterdam UMC, location AMC Amsterdam
Netherlands Reinier de Graaf Gasthuis Delft
Netherlands Deventer hospital Deventer Overijssel
Netherlands Martini hospital Groningen

Sponsors (4)

Lead Sponsor Collaborator
Deventer Ziekenhuis Dutch National Health Care Institute, University of Twente, Utrecht University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with sustained unresponsiveness to consumption of a specific allergenic food 4 weeks after stopping the 1-year oral immunotherapy (OIT) Definition of sustained unresponsiveness: a participant who passed an oral food challenge (OFC) to 4.2 gram of the allergenic protein.
Definition of the allergenic protein: the allergenic protein which induced an allergic response at an OFC at the start of the study, and was administered to the patient during the OIT (i.e. milk, egg, peanut, hazelnut, cashew or walnut).
Timing of the OFC: week 57 (52 weeks of OIT, followed by a 4-week allergenic food-free interval)
Primary Percentage of tolerant participants at week 78 In children achieving sustained unresponsiveness (outcome 1), the allergen is introduced into the diet by parents at a regular base. Six months after discontinuation of the OIT, tolerance to the specific allergenic protein is assessed.
Definition of tolerant: Percentage of children with uncomplicated (i.e. without any allergic symptoms) consumption at home of a full dose of the specific allergenic protein (e.g. a glass of milk or a sandwich with peanut butter).
week 78 = 6 months after stop of the 1-year oral immunotherapy
Primary Cost-effectiveness ratio at 18 months (week 78). Incremental cost-effectiveness ratio (ICER) at 18 months (week 78). Costs associated with oral immunotherapy will be measured in Euros. Effectiveness will be considered as percentage of tolerant participants at week 78. 18 months (week 78).
Primary Cost-utility ratio at 18 months (week 78). Incremental cost-utility ratio (ICUR) will be calculated for both groups using health-related quality of life (HRQoL) scores from the AQoL-6D (assessment of quality of life - 6 dimensions) and converted to utility scores and will be expressed in euros per QALY. 18 months (week 78): at the end of the study period.
Secondary Health related quality of life of children, during the 1-year OIT and six months after the therapy (week 78) Children's quality of life as measured by:
- Food Allergy Quality of Life Questionnaire - parental form (FAQLQ-PF) This questionnaire consists of 14 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no impact of food allergy on quality of life), maximum score is 84 (high impact of food allergy on quality of life)
during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)
Secondary Occurrence of Adverse Event(s) Related to Oral Immunotherapy up to 65 weeks study participation (Serious) adverse events related to oral immunotherapy during build-up (up to 3 months) and 1-year oral immunotherapy, total 65 weeks
Secondary Levels of allergy-related immune parameters Levels of allergen specific IgE and IgG4 at start of the therapy and after 6 and 12 months maintenance therapy
Secondary adherence Rate of daily providing the oral immunotherapy during 1 year oral immunotherapy
Secondary Health related quality of life of parents, during the 1-year OIT and six months after the therapy (week 78) Parental quality of life as measured by:
- Food Allergy Quality of Life- Parental Burden (FAQL-PB) This questionnaire consists of 17 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no parental burden), maximum score is 102 (severe parental burden)
during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)
See also
  Status Clinical Trial Phase
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05839405 - Food Allergy in the Brain
Completed NCT02552537 - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Phase 4
Completed NCT01634737 - Crustacean Allergy and Dust Mites Sensitization N/A
Recruiting NCT05521711 - TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation N/A
Completed NCT05072665 - Fast Allergy Sensitivity Test N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Recruiting NCT03265262 - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy N/A
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02490007 - Pertussis Immunisation and Food Allergy
Recruiting NCT03151252 - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract N/A
Completed NCT02159833 - Intranasal Diagnostics in Food Allergy: a Feasibility Study N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02377284 - Prevention and Management of Food Allergies N/A
Completed NCT02640560 - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish N/A
Enrolling by invitation NCT06097572 - Improved Diagnostics in Food Allergy Study N/A
Recruiting NCT04606615 - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting NCT05785299 - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy N/A
Not yet recruiting NCT06112873 - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed NCT03337802 - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring N/A